Brokerages Anticipate Health Catalyst, Inc. (NASDAQ:HCAT) to Post -$0.27 Earnings Per Share

Equities research analysts predict that Health Catalyst, Inc. (NASDAQ:HCAT) will announce ($0.27) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Health Catalyst’s earnings. The lowest EPS estimate is ($0.31) and the highest is ($0.24). Health Catalyst also reported earnings per share of ($0.27) during the same quarter last year. The firm is scheduled to report its next quarterly earnings results on Tuesday, November 10th.

On average, analysts expect that Health Catalyst will report full-year earnings of ($0.81) per share for the current financial year, with EPS estimates ranging from ($1.03) to ($0.66). For the next financial year, analysts forecast that the business will post earnings of ($0.59) per share, with EPS estimates ranging from ($0.84) to ($0.23). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that that provide coverage for Health Catalyst.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.24. Health Catalyst had a negative net margin of 46.91% and a negative return on equity of 20.74%. The company had revenue of $43.26 million for the quarter, compared to analysts’ expectations of $42.19 million. During the same quarter in the previous year, the company posted ($0.21) EPS. The firm’s quarterly revenue was up 17.5% on a year-over-year basis.

Several brokerages have issued reports on HCAT. Stifel Nicolaus lifted their target price on shares of Health Catalyst from $36.00 to $37.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. SVB Leerink boosted their price target on shares of Health Catalyst from $32.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, July 10th. Citigroup initiated coverage on shares of Health Catalyst in a research report on Tuesday, July 14th. They set a “buy” rating and a $40.00 price target on the stock. Truist Financial boosted their price target on shares of Health Catalyst from $36.00 to $43.00 in a research report on Wednesday, August 12th. Finally, BidaskClub cut shares of Health Catalyst from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 7th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $38.82.

In related news, CEO Daniel D. Burton sold 84,742 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $34.85, for a total value of $2,953,258.70. Following the sale, the chief executive officer now directly owns 199,662 shares in the company, valued at approximately $6,958,220.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Linda Llewelyn sold 2,242 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $35.46, for a total transaction of $79,501.32. Following the completion of the sale, the insider now owns 27,619 shares in the company, valued at $979,369.74. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 764,968 shares of company stock worth $24,863,791. 22.10% of the stock is owned by insiders.

A number of large investors have recently modified their holdings of HCAT. Winslow Evans & Crocker Inc. purchased a new stake in Health Catalyst during the second quarter worth about $32,000. Nisa Investment Advisors LLC purchased a new stake in Health Catalyst during the third quarter worth about $51,000. Advisor Group Holdings Inc. increased its stake in Health Catalyst by 415.8% during the second quarter. Advisor Group Holdings Inc. now owns 2,388 shares of the company’s stock worth $70,000 after purchasing an additional 1,925 shares during the period. HighMark Wealth Management LLC increased its stake in Health Catalyst by 274.4% during the third quarter. HighMark Wealth Management LLC now owns 1,928 shares of the company’s stock worth $71,000 after purchasing an additional 1,413 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Health Catalyst by 80.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,555 shares of the company’s stock worth $75,000 after purchasing an additional 1,140 shares during the period. Institutional investors own 85.53% of the company’s stock.

HCAT traded down $0.43 on Friday, hitting $34.09. 1,979 shares of the company’s stock were exchanged, compared to its average volume of 654,231. Health Catalyst has a fifty-two week low of $17.48 and a fifty-two week high of $41.26. The company has a current ratio of 7.91, a quick ratio of 7.91 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average price of $35.02 and a 200-day moving average price of $31.36. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -11.54 and a beta of 0.54.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was founded in 2008 and is headquartered in Salt Lake City, Utah.

Featured Article: How to Invest in a Bull Market

Get a free copy of the Zacks research report on Health Catalyst (HCAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.